Publication date: May 01, 2025
Immune checkpoint inhibitors (ICIs) might increase the risk of major adverse cardiovascular events (MACEs). This study aimed to evaluate the risk of MACE in patients with melanoma after ICI initiation. We conducted a before-after cohort study using claims data from Optum’s deidentified Clinformatics Data Mart Database. We included adult patients with melanoma who received any approved ICI between 2011 and 2021 with a minimum of 12 months of observable data before ICI. The main outcome was time to first MACE (myocardial infarction, coronary revascularization, stroke, heart failure hospitalization) and rate of MACE before and after ICI, ascertained using International Classification of Diseases, 9th/10th Revision diagnostic codes. Hazard ratio (HR) and incidence rate ratio (IRR) were calculated. We identified 4024 patients with ICI-treated melanoma. Mean age was 67. 4 years (SD 14. 1), 36% were women; 3066 (76. 2%) received monotherapy and 958 (23. 8%) combination immunotherapy. A total of 160 (4%) patients had a MACE before ICI and 224 (5. 6%) after ICI (HR, 1. 76; 95% CI, 1. 47-2. 12). MACE rate in the year before ICI was 56. 16 per 1000 person-years compared with 80. 91 per 1000 person-years the year after ICI (IRR, 1. 44; 95% CI, 1. 21-1. 72). Ten cases of myocarditis were observed after ICI, 50% of them had a MACE. Risk factors associated with MACE after ICI were prior MACE, other cardiovascular conditions, hypertension, and older age. Glucocorticoid use was not associated with MACE. Our results suggest that ICI might increase the risk of MACE in patients with melanoma during the first year after ICI.
| Concepts | Keywords |
|---|---|
| 10th | cardiotoxicity |
| Clinformatics | cardiovascular disease |
| Hospitalization | immune checkpoint inhibitors |
| Myocardial | melanoma |
| Women |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Melanoma |
| pathway | KEGG | Melanoma |
| disease | MESH | myocardial infarction |
| disease | MESH | stroke |
| disease | MESH | heart failure |
| drug | DRUGBANK | Pentaerythritol tetranitrate |
| disease | MESH | myocarditis |
| disease | MESH | hypertension |
| disease | MESH | cardiovascular disease |